Confidentiality Is Slowing Down Cancer Care.

Confidentiality Is Slowing Down Cancer Care.

One Idea Worth Acting On.

A breakthrough oncology drug receives FDA approval.

The sponsor wants rapid adoption as the new standard of care.

Independent guideline committees request access to the full submission data to validate the evidence.

The company hesitates. Confidentiality restrictions. Proprietary information.

The therapy that could change treatment practice for thousands of patients sits outside the guideline while the evidence debate continues.

What's Actually Happening

Regulatory submissions contain enormous evidence packages — clinical data, subgroup analyses, safety findings, exploratory endpoints, operational details. Much of this is treated as confidential or proprietary.

At the same time, organizations like the National Comprehensive Cancer Network are attempting to rapidly evaluate emerging therapies so clinical guidelines can reflect the newest standards of care as quickly as possible.

But independent guideline panels operate under strict transparency expectations. As Dr. Robert Carlson, former CEO of NCCN and contributor to Voices of Oncology, explains: guideline organizations cannot rely on confidential evidence that cannot be publicly reviewed or referenced. The integrity of the guideline depends on its independence. That independence requires access to the full evidence base.

When critical evidence cannot be openly evaluated, guideline integration slows — and physician adoption follows suit.

Why This Matters

Clinical practice guidelines are one of the most important drivers of real-world treatment adoption in oncology. Physicians use them to make prescribing decisions. Payers use them to make coverage decisions. Institutions use them to set formularies.

A drug that wins regulatory approval but sits outside NCCN guidelines for months or years because the evidence cannot be fully evaluated is not reaching the patients who need it. The approval happened. The access did not.

This is not a hypothetical risk. The gap between regulatory approval and guideline integration is one of the most consistent and least discussed delays in patient access — and confidentiality structures are a meaningful contributor to it.

Where It Breaks in the Real World

A sponsor submits a therapy under accelerated approval based on a surrogate endpoint. The agency approves. The NCCN panel convenes to evaluate inclusion.

The panel needs the full supporting data — including the subgroup analyses and the safety database — to evaluate the evidence with the rigor their guideline standards require. The sponsor provides a summary. The panel requests the underlying data. The sponsor cites confidentiality.

The guideline designation is deferred pending confirmatory data. The therapy sits in a category that limits its real-world use. Patients wait.

What Needs to Change

The industry needs to recognize that the approval decision and the guideline decision serve the same ultimate purpose: getting effective therapies to patients. Treating them as adversarial processes — where the sponsor controls the evidence that guideline bodies need to do their job — produces friction that serves neither goal.

This does not require abandoning legitimate IP protections. It requires building evidence-sharing frameworks that allow independent scientific review without exposing commercially sensitive information. Those frameworks are achievable. They require will more than technology.

The Bottom Line

Approval is not access. A drug that is approved but not in the guidelines is not reaching the patients who need it.

Confidentiality structures that made sense in a slower era of drug development are now contributing to the access gap the industry says it wants to close.

Add Your Voice — Where are you seeing this? What's working — and what's not?